Literature DB >> 31309590

Myocardial fibrosis in chagas disease and molecules related to fibrosis.

Ana T Chaves1, Cristiane A S Menezes2, Henrique S Costa1, Maria C P Nunes1, Manoel O C Rocha1.   

Abstract

Chronic Chagas cardiomyopathy (CCC) is responsible for the disease's greater morbidity and poor prognosis. Although understanding the pathophysiology of CCC and the fundamentals of its clinical management derives from research related to other cardiomyopathies, there are peculiarities that distinguish CCC from the others. CCC is the most fibrous heart disease, and its myocardial involvement is important as it disorganizes or disrupts the extracellular matrix, creating an environment conducive to the formation of arrhythmogenic foci. It is also considered the most arrhythmogenic of the known heart diseases, giving rise to complex arrhythmias, usually associated with varying degrees of stimulus conduction disorders. The central proposal of this review is to describe a possible association between the distribution and degree of myocardial fibrosis and cardiac arrhythmogenicity in patients with Chagas cardiomyopathy, drawing attention to the importance of noninvasive biomarkers for the quantification of myocardial fibrosis.
© 2019 John Wiley & Sons Ltd.

Entities:  

Keywords:  cardiac fibrosis markers; cardiac remodelling; chronic Chagas cardiomyopathy; myocardial fibrosis; ventricular arrhythmic

Mesh:

Substances:

Year:  2019        PMID: 31309590     DOI: 10.1111/pim.12663

Source DB:  PubMed          Journal:  Parasite Immunol        ISSN: 0141-9838            Impact factor:   2.280


  7 in total

Review 1.  Chagas Cardiomyopathy: From Romaña Sign to Heart Failure and Sudden Cardiac Death.

Authors:  Antonia Pino-Marín; Germán José Medina-Rincón; Sebastian Gallo-Bernal; Alejandro Duran-Crane; Álvaro Ignacio Arango Duque; María Juliana Rodríguez; Ramón Medina-Mur; Frida T Manrique; Julian F Forero; Hector M Medina
Journal:  Pathogens       Date:  2021-04-22

2.  Vaccine-linked chemotherapy induces IL-17 production and reduces cardiac pathology during acute Trypanosoma cruzi infection.

Authors:  Julio V Cruz-Chan; Liliana E Villanueva-Lizama; Leroy Versteeg; Ashish Damania; Maria José Villar; Cristina González-López; Brian Keegan; Jeroen Pollet; Fabian Gusovsky; Peter J Hotez; Maria Elena Bottazzi; Kathryn M Jones
Journal:  Sci Rep       Date:  2021-02-05       Impact factor: 4.379

3.  Cardiac Fibrosis and Changes in Left Ventricle Function in Patients with Chronic Chagas Heart Disease.

Authors:  João Bosco de Figueiredo Santos; Ilan Gottlieb; Eduardo Marinho Tassi; Gabriel Cordeiro Camargo; Jacob Atié; Sérgio Salles Xavier; Roberto Coury Pedrosa; Roberto Magalhães Saraiva
Journal:  Arq Bras Cardiol       Date:  2021-12       Impact factor: 2.000

4.  The repositioned drugs disulfiram/diethyldithiocarbamate combined to benznidazole: Searching for Chagas disease selective therapy, preventing toxicity and drug resistance.

Authors:  Juliana Almeida-Silva; Diego Silva Menezes; Juan Mateus Pereira Fernandes; Márcio Cerqueira Almeida; Deyvison Rhuan Vasco-Dos-Santos; Roberto Magalhães Saraiva; Alessandra Lifsitch Viçosa; Sandra Aurora Chavez Perez; Sônia Gumes Andrade; Ana Márcia Suarez-Fontes; Marcos André Vannier-Santos
Journal:  Front Cell Infect Microbiol       Date:  2022-07-29       Impact factor: 6.073

5.  Galectin-3 and fibrosis intensity in Chronic Chagas Cardiomyopathy: a systematic review.

Authors:  Ana Thereza Chaves; Ana Laura Grossi de Oliveira; Nathalia Sernizon Guimarães; Isabela Cristina Magalhães; Cristiane Alves da Silva Menezes; Manoel Otávio da Costa Rocha
Journal:  Rev Inst Med Trop Sao Paulo       Date:  2022-06-24       Impact factor: 2.169

6.  Genome-wide association study for Chagas Cardiomyopathy identify a new risk locus on chromosome 18 associated with an immune-related protein and transcriptional signature.

Authors:  Ester Cerdeira Sabino; Lucas Augusto Moysés Franco; Gabriela Venturini; Mariliza Velho Rodrigues; Emanuelle Marques; Lea Campos de Oliveira-da Silva; Larissa Natany Almeida Martins; Ariela Mota Ferreira; Paulo Emílio Clementino Almeida; Felipe Dias Da Silva; Sâmara Fernandes Leite; Maria do Carmo Pereira Nunes; Desiree Sant'Ana Haikal; Claudia Di Lorenzo Oliveira; Clareci Silva Cardoso; Jonathan G Seidman; Christine E Seidman; Juan P Casas; Antonio Luiz Pinho Ribeiro; Jose E Krieger; Alexandre C Pereira
Journal:  PLoS Negl Trop Dis       Date:  2022-10-10

7.  Interleukin-9 in Immunopathology of Trypanosoma cruzi Experimental Infection.

Authors:  Nadjania Saraiva de Lira Silva; Cristina Mary Orikaza; Fabiana Rodrigues de Santana; Luana Aguiar Dos Santos; Bruno Ramos Salu; Maria Luiza Vilela Oliva; Rita de Cássia Sinigaglia; Renato Arruda Mortara
Journal:  Front Cell Infect Microbiol       Date:  2021-10-15       Impact factor: 5.293

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.